bioRxiv · 10.64898/2026.03.29.713052
Novel Engineered AAV Variants Demonstrate Superior Blood-Brain Barrier Penetration and Safety in Non-Human Primates
Abstract
Systemic delivery of adeno-associated virus (AAV) for gene therapy of central nervous system (CNS) disorders is limited by inefficient blood-brain barrier (BBB) penetration and dose-limiting toxicity in peripheral organs, notably the liver and dorsal root ganglia (DRG)1-5. Here, we report the development of novel AAV variants via a proprietary capsid engineering platform (REACH). In non-human primates (NHPs), intravenous administration of lead variants resulted in transgene expression levels in the brain that were 600-2000 fold higher than AAV9 at the RNA level, concomitant with a 10-50 fold reduction in liver tropism and minimal off-target exposure in the heart and DRG. These engineered capsids achieve unprecedented, pan-CNS transduction with a markedly improved safety profile, representing a transformative platform for treating a broad spectrum of neurological diseases.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Wang, Z., Li, H., Xu, X., Sun, Z., He, R., Zhang, L., Yu, M., Wang, S., Hu, C., Liu, L., Ren, L., Xu, Y., Xiao, T., Li, D., Sun, B., Luo, Y., An, Z.. 2026-04-01. Novel Engineered AAV Variants Demonstrate Superior Blood-Brain Barrier Penetration and Safety in Non-Human Primates. https://doi.org/10.64898/2026.03.29.713052
Cite the original work for its findings. Save a collection to share your selection of sources.